Recently, MET inhibitors combined with EGFR-TKIs have been studied clinically in NSCLC patients, because NSCLC patients may become resistant to EGFR inhibitors due to secondary EGFR mutations, MET amplification, or HGF overexpression. This evidence concerns the gene MET and non-small cell lung carcinoma.